Inventor · disambiguated record
Stephen Sazinsky
Also filed as: SAZINSKY STEPHEN · SAZINSKY STEPHEN L · SAZINSKY STEPHEN LAEL
11 granted patents·8 pending applications·38 citations·filing 2008–2025
87Inventor score
Files withJOUNCE THERAPEUTICS INC9KELONIA THERAPEUTICS INC4VERSEAU THERAPEUTICS INC4MERRIMACK PHARMACEUTICALS INC1WITTRUP K DANE1
Top patents by PatentIndex Score
19 records- 0192US12269882B1Antigen binding polypeptidesKELONIA THERAPEUTICS INC·Filed 2024·Granted Apr 8, 2025·3 cites·30 claims
- 0291US11905329B2Anti-PD-1 antibodies and uses thereofJOUNCE THERAPEUTICS INC·Filed 2022·Granted Feb 20, 2024·1 cites·35 claims
- 0390US12440564B2Compositions for treating cancerKELONIA THERAPEUTICS INC·Filed 2024·Granted Oct 14, 2025·1 cites·25 claims
- 0490US8815237B2Aglycosylated immunoglobulin mutantsWITTRUP K DANE·Filed 2008·Granted Aug 26, 2014·16 cites·19 claims
- 0587US10654929B2Antibodies to PD-1 and uses thereofJOUNCE THERAPEUTICS INC·Filed 2017·Granted May 19, 2020·3 cites·36 claims
- 0687US10023635B2Antibodies to ICOSJOUNCE THERAPEUTICS INC·Filed 2016·Granted Jul 17, 2018·8 cites·47 claims
- 0783US12403194B2Compositions for treating cancerKELONIA THERAPEUTICS INC·Filed 2024·Granted Sep 2, 2025·0 cites·25 claims
- 0883US11384147B2Anti-PD-1 antibodies and uses thereofJOUNCE THERAPEUTICS INC·Filed 2020·Granted Jul 12, 2022·1 cites·72 claims
- 0982US10570203B2Antibodies to ICOSJOUNCE THERAPEUTICS INC·Filed 2018·Granted Feb 25, 2020·3 cites·24 claims
- 1080US10968277B2Gene signatures for determining ICOS expressionJOUNCE THERAPEUTICS INC·Filed 2016·Granted Apr 6, 2021·2 cites·21 claims
- 1171US12435140B2Antigen binding polypeptidesKELONIA THERAPEUTICS INC·Filed 2025·Granted Oct 7, 2025·0 cites·30 claims
- 1264US2021171635A1Antibodies to ICOSJOUNCE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1357US2021340256A1Gene Signatures for Determining ICOS ExpressionJOUNCE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1438US2023348603A1Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereofVERSEAU THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1536US2022363752A1Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereofVERSEAU THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1636US2022251233A1Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereofVERSEAU THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1736US2019077870A1Engineered trail for cancer therapyMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1834US2022396627A1Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereofVERSEAU THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1931US2016200815A1Antibodies that inhibit tim-3:lilrb2 interactions and uses thereofJOUNCE THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen Sazinsky files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →